AstraZeneca, Novo Nordisk: anti-obesity drugs to lift companies that fill ‘skinny pens’
Global syringe-filling facilities are struggling to cope with rising demand for anti-obesity drugs, which require injection pens. IGTV's @AngelineOng investigates which companies could benefit from ‘fill-finish’ demand.
(Video Transcript)
Slimming demand set to create multi-billion-dollar market
Demand is booming for a self-injection, weight-loss drug and, by some estimates, the anti-obesity market could be worth some $100 billion within a decade. There are Novo Nordisk, Wegovy, Eli Lilly, VetBound, to name just a few in the market.
I can also tell you that AstraZeneca has also recently acquired in this space. There are also Amgen and Pfizer, all in this race to provide anti-obesity drugs. Now sales of Wegovy, the first of a new generation of obesity treatment, which mimics the body's appetite suppressing hormones. This is a drug made by Novo Nordisk, and which they've sold since its launch in the US in June 2021.
Demand soars despite unknown risks
What's interesting is that demand has soared despite the health experts warning that the risks are not yet known and despite the injections being relatively expensive for middle-income earners. We're talking about more than $1,000 for a month's supply. Demand is so high that even diabetes sufferers in need of similar drugs are finding it hard to get hold of their treatments.
So where is the salad dressing? Well if you think investing in these drug makers holds too much risk for you, think about exposure to the companies that make the injection pens instead. They're also known as skinny pens. Big drug makers making these anti-obesity drugs admit there is a huge shortage in so-called fill finish work.
Dire shortage of skinny pen injections
This is the process of filling fringes in sterile conditions to avoid contamination before these pens are then assembled, packaged and then shipped off to wholesalers like pharmacies and clinics. There is no pill version of this anti-obesity drug on the shelf just yet.
Companies like Catalan and Thermo, for example, just in the Thermo's chart here, they are behind a lot of the fill finish work that many drug companies, if they don't have the capacity, look to to fill this capacity in Catalan and Thermo. So Barclays, Ameth, Luke, Surgott are in a really good position, especially in the near-term until big drug makers can build their own fill finish facilities.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Act on share opportunities today
Go long or short on thousands of international stocks with spread bets and CFDs.
- Get full exposure for a comparatively small deposit
- Trade on spreads from just 0.1%
- Get greater order book visibility with direct market access
See opportunity on a stock?
Try a risk-free trade in your demo account, and see whether you’re on to something.
- Log in to your demo
- Take your position
- See whether your hunch pays off
See opportunity on a stock?
Don’t miss your chance – upgrade to a live account to take advantage.
- Trade a huge range of popular stocks
- Analyse and deal seamlessly on fast, intuitive charts
- See and react to breaking news in-platform
See opportunity on a stock?
Don’t miss your chance. Log in to take advantage while conditions prevail.
Live prices on most popular markets
- Equities
- Indices
- Forex
- Commodities
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
